Document:

Exhibit
10.93

 

EMPLOYMENT
AGREEMENT

 

THIS AGREEMENT (along with all Exhibits attached
hereto, hereinafter referred to as the “Agreement”) is made effective as of March 25,
2010 by and between BIO-key International, Inc., a Delaware corporation
with its principal place of business at 3349 Highway 138 Building D Suite B
Wall, NJ 07719 (the “Company”), and Michael W. DePasquale residing at 704
Michael Drive, Toms River, NJ 08753 (the “Executive”).

 

WITNESSETH:

 

WHEREAS, the Company desires to
secure the employment of the Executive in accordance with the provisions of
this Agreement; and

 

WHEREAS, the Executive desires and is willing to
be employed by the Company in accordance herewith.

 

NOW THEREFORE, in consideration of the premises and
mutual covenants contained herein, and other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, and intending to
be legally bound hereby, the parties hereto agree as follows:

 

1.             Employment  Term.  This Agreement shall remain in full force and
effect for a term commencing on the Effective Date hereof and expiring on the first (1st)
anniversary hereof (the “Initial Term”), or, if earlier, until the employment
relationship is terminated pursuant to Section 4 hereof.  Upon the expiration of the Initial Term, this
Agreement will be renewed automatically for successive one-year periods (each,
a “Renewal Term”), unless sooner terminated in accordance with the provisions
of Section 4 or unless the Company gives written notice of non-renewal at
least two (2) months prior to the date on which the Initial Term or the
applicable Renewal Term, as the case may be, would otherwise end.

 

2.                                       Duties; Exclusive  Services  and  Best  Efforts.

 

(a)           Duties.  The Executive shall hold the position
assigned by the Company and serve in such position in accordance with the
Company’s Certificate of Incorporation and By-Laws and in accordance with the
ultimate control of the Board of Directors of the Company (the “Board”).

 

(b)           Exclusive Services and Best
Efforts.  The Executive agrees to
devote his best efforts, energies and skill to the faithful, competent and
diligent discharge of the duties and responsibilities attributable to his
position, and to this end, will devote his full-time attention to the business
and affairs of the Company.  The
Executive also agrees that he shall not take personal advantage of any business
opportunities that arise during his employment that may benefit the
Company.  All material facts regarding
such opportunities must be promptly reported 

 

1

 

to the Board for its consideration. In addition, the Company
acknowledges and agrees that the Executive shall be permitted to engage in and
pursue such contemporaneous activities and interests as the Executive may
desire, for personal profit or otherwise, provided such activities do not
interfere with the Executive’s performance of his duties and obligations
hereunder.

 

3.             Compensation. 
On and after the commencement of Executive’s employment, the Executive
shall receive, for all services rendered to the Company hereunder, the
following:

 

(a)           Base Salary.  The Executive shall be paid a base annual
salary (“Base Salary”) equal to Two Hundred Fifty Thousand Dollars  ($250,000).  Base
Salary shall be payable in equal installments in accordance with the Company’s
general salary payment policies but no less frequently than monthly.  Base Salary may be increased annually, or at
such other intervals, as the Board or Compensation Committee thereof shall
determine from time to time.

 

(b)           Performance
Bonus.  In addition to Base Salary,
the Executive may be granted a performance bonus, the amount, if any, and
timing of which shall determined by the Board in its sole discretion.

 

(c)           Benefits.  Executive shall be eligible to participate in
any of the Company’s employee welfare or health benefit plans (including, but
not limited to, life insurance, health, medical and dental plans).

 

(d)           Vacation.  The Executive shall be eligible for four (4) weeks
of paid vacation each year of his employment hereunder.  The Executive shall be permitted to carry
over and accrue unused vacation time for a period of up to two years.

 

(e)           Expenses.  Subject to and in accordance with the Company’s
policies and procedures, and, upon presentation of itemized accounts, the
Executive shall be reimbursed by the Company for reasonable and necessary
business-related expenses, which expenses are incurred by the Executive on
behalf of the Company.

 

(f)            Deductions from
Salary and Benefits.  The Company
will withhold from any salary or benefits payable to the Executive all federal,
state, local, and other taxes and other amounts as required by law, rule or
regulation.

 

4.             Termination. 
This Agreement may be terminated by either the Executive or the Company
at any time, subject only to the provisions of this Section 4.

 

(a)           Voluntary Termination.  If Executive terminates his own employment,
the Company shall be released from any and all further obligations under this
Agreement, except that the Company shall be obligated to pay Executive his
salary and benefits owing to Executive through the effective date of
termination.  Executive shall also be
entitled to any reimbursement 

 

2

 

owed in accordance with Section 3(e).  Executive’s obligations under Sections 5, 7,
8 and 9 hereof and shall survive the termination of Executive’s employment, and
Executive shall remain bound thereby.

 

(b)           Death.  This Agreement shall terminate on the date of
the Executive’s death, in which event salary, benefits, and reimbursable
expenses owing to the Executive through the date of the Executive’s death shall
be paid to his estate.

 

(c)           Disability.  If, during the term of this Agreement, in the
opinion of the Company, the Executive, because of physical or mental illness or
incapacity or disability, shall become unable to perform, with or without
reasonable accommodation, substantially all of the duties and services required
of him under this Agreement for a period one hundred eighty (180) days during
any twelve-month period, the Company may, upon at least ten (10) days
prior written notice given at any time after the expiration of such one hundred
eighty (180) day period, notify the Executive of its intention to terminate
this Agreement as of the date set forth in the notice.  In case of such termination, the Executive
shall be entitled to receive salary, benefits, and reimbursable expenses owing
to the Executive through the date of termination of the Initial Term or
applicable Renewal Term, as the case may be. 
The Company shall have no further obligation or liability to the
Executive.  The Executive’s obligations
under Sections 5, 7 8 and 9 hereof shall survive the termination of Executive’s
employment, and Executive shall remain bound thereby.

 

(d)           Termination by Employer for Cause.
This Agreement may be terminated by the Company for Cause (as defined below) at
any time.  Upon such termination for
Cause, the Company shall be released from any and all further obligations under
this Agreement, except that the Company shall be obligated to pay the Executive
his salary and benefits owing to the Executive through the effective date of
such termination.  The Executive shall
also be entitled to any reimbursement owed in accordance with Section 3(h).
 The Executive’s obligations under
Sections 5, 7, 8 and 9 hereof shall survive the termination of Executive’s
employment, and Executive shall remain bound thereby.

 

As used herein, “Cause”
shall include, but is not limited to, the following conduct of the Executive:

 

(i)            Breach of any material provision of
this Employment Agreement by the Executive if not cured within two (2) weeks
after receiving written notice thereof;

 

(ii)           Misconduct as an
Executive of the Company, including but not limited to, misappropriating funds
or property of the Company; any attempt to obtain any personal profit from any
transaction in which the Executive has an interest that is adverse to the
Company or any breach of the duty of loyalty and fidelity to the Company; or
any other material act or omission of the Executive which substantially impairs
the Company’s ability to conduct its ordinary business in its usual manner;

 

3

 

(iii)          Material neglect or
refusal to perform the duties assigned to the Executive pursuant to this
Employment Agreement if not cured within two (2) weeks after receiving
notice thereof;

 

(iv)          Conviction of a
felony or plea of guilty or nolo contendere
to a felony;

 

(v)           Acts of dishonesty
or moral turpitude by the Executive that are detrimental to the Company or any
other act or omission which subjects the Company or any of its affiliates to
public disrespect, scandal, or ridicule, or that causes the Company to be in
violation of governmental regulations that subjects the Company either to
sanctions by governmental authority or to civil liability to its Executives or
third parties;

 

(vi)          Disclosure or use of
confidential information of the Company, other than as specifically authorized
and required in the performance of the Executive’s duties.

 

(e)          Termination by Employer Without
Cause.  Upon termination of this
Agreement by the Company without Cause (including without limitation
non-renewal by the Company without Cause), the Company shall be released from
any and all further obligations under this Agreement, except that the Executive
shall be paid his Base Salary and benefits earned but unpaid through the date
of termination and continue to be paid in the same manner as before
termination, (i) his then current monthly Base Salary and benefits for a
period of time equal to the greater of nine (9) months or the remaining
term of this Agreement, beginning six months following the termination date or
such earlier date as may be permitted under Section 409A of the Internal Revenue
Code, as amended (“Section 409A”), (ii) any prorated bonus
established by the Board that is earned during the then current bonus year,
payable six months following the termination date or such earlier date as may
be permitted under Section 409A and (iii) Executive shall have the
right to extend the exercise date of his existing stock options for twenty-four
(24) months after the termination date (or such shorter period that shall not
exceed the latest date on which the option could have expired by its terms or
the tenth anniversary of the date of grant), on a “cashless exercise” basis,
if, and only if, the Executive signs a valid general release of all claims
against the Company, its affiliates, subsidiaries, officers, directors and
agents, in a form provided by the Company. 
The Company shall have no further obligation or liability to the
Executive.  The Executive’s obligations
under Sections 5, 7, 8 and 9 hereof and shall survive the termination of the
Executive’s employment, regardless of the circumstances of any such
termination, and the Executive shall remain bound thereby.

 

(f)            Change of
Control.  If a Change of Control (as
defined below) occurs, and either (i) the Executive is not offered
continued employment with the Company or any successor thereto or (ii) within
five (5) years following such Change of Control, the Company or any
successor thereto terminates the Executive’s employment without Cause, then, in
lieu of any 

 

4

 

applicable payments to Executive under Section 4(e),
as of the date of such termination the Executive shall be entitled to be paid an amount
equal to (A) his Base Salary and benefits earned but unpaid through the
date of termination, plus (B) any prorated bonus established by the Board
that is earned during the then current bonus year, payable six months following
the termination date or such earlier date as may be permitted under Section 409A,
plus (C) two (2) times his then current Base Salary, in a single lump
sum payment to be made six months following the termination date or such
earlier date as may be permitted under Section 409A.  As used herein, “Change of Control” means (x) the
acquisition of beneficial ownership (as defined in Rule 13d-3 under the
Securities Exchange Act of 1934, as amended) directly or indirectly by any
person or entity of securities of the Company representing a majority of the
combined voting power of the Company’s then outstanding securities, other than
an acquisition of securities for investment purposes pursuant to a bona fide
financing of the Company; (y) a merger or consolidation of the Company
with any other entity in which the holders of the voting securities of the
Company prior to the merger or consolidation do not own more than 50% of the
total voting securities of the surviving entity; or (z) the sale or
disposition by the Company of all or substantially all of the Company’s assets
other than a sale or disposition of assets to an affiliated person or entity.

 

(g)           Termination by Mutual Agreement.  This Agreement may be terminated at any time
by mutual agreement of the Executive and the Company.

 

5.             Non-Competition  and  Business  Opportunities.

 

(a)           Non-Competition.  The Executive understands that the Company is
in the business of developing and licensing finger print identification
technologies, and distributing products incorporating such technologies, to
original equipment manufacturers and end users. 
The Executive agrees that during the period of his employment hereunder
and for a period of one (1) year thereafter, the Executive will not
directly or indirectly: (i) market, sell or perform  services such as are offered or conducted by
the Company, its affiliates and subsidiaries during the period of his
employment, to any customer or client of the Company or “Prospective Customer”
or client of the Company; or (ii) engage, directly or indirectly, whether
as principal or as agent, officer, director, Executive, consultant,
shareholder, or otherwise, alone or in association with any other person, corporation
or other entity, in any “Competing Business”. For the purpose of this Section 5(a) “Prospective
Customer” shall mean any person with whom the Company has engaged in any
substantial discussion or negotiation regarding the use of the Company’s products
or services.  For purposes of this Section 5(a),
the term “shareholder” shall exclude any interest owned by Employer in a public
company to the extent the Employer owns less than ten percent (10%) of any such
company’s outstanding common stock.  For
the further purposes of this Agreement, the term “Competing Business” shall
mean any person, corporation or other entity developing and/or licensing finger
print identification technologies or distributing products incorporating such
technologies, within the United States, to original equipment manufacturers and
end users at the time of such termination or non-renewal. Due to the nature of
the markets served and the technology and products to be developed and marketed
by the 

 

5

 

Company which are intended to be available on a national basis, the
restrictions set forth in this Section 5(a) can not be limited to a
specific geographic area within the United States.

 

(b)           Business Opportunities.  The Executive agrees that during the period
of his employment hereunder, the Executive will not take personal advantage of
any business opportunities that are similar or substantially similar to the
business of the Company.  In addition,
all material facts regarding any such business opportunities must be promptly
and fully disclosed by the Executive to the Board of Directors as soon as the
Executive becomes aware of any opportunity, and in no event later than
forty-eight (48) hours after learning of such opportunity.  Business opportunities covered by this Section 5(b) shall
include, but are not limited to, opportunities relating to the development and
licensing of finger print identification technologies or the distribution of
products incorporating such technologies to original equipment manufacturers
and end users.

 

(c)           Non-Solicitation. The
Executive agrees that during the period of employment hereunder and for a
period of one (1) year thereafter, the Executive will not request or
otherwise attempt to induce or influence, directly or indirectly, any present
customer, distributor or supplier, or Prospective Customer, distributor or
supplier, of the Company, or other persons sharing a business relationship with
the Company to cancel, to limit or postpone their business with the Company, or
otherwise take action which might be to the material disadvantage of the
Company. The Executive agrees that during the period of employment hereunder
and for a period of one (1) year thereafter, Executive will not hire or
solicit for employment, directly or indirectly, or induce or actively attempt
to influence, hire or solicit, any Executive, agent, officer, director,
contractor, consultant or other business associate of the Company to terminate
his or her employment or discontinue such person’s consultant, contractor or
other business association with the Company.

 

(d)           Scope.  The parties hereto agree that, due to the
nature of the Company’s business, the duration and scope of the non-competition
and non-solicitation provisions set forth above are reasonable.  In the event that any court determines that
the duration or the geographic scope, or both, are unreasonable and that such
provisions are to that extent unenforceable, the parties hereto agree that such
provisions shall remain in full force and effect for the greatest time period
and in the greatest area that would not render it unenforceable. The parties
intend that the non-competition and non-solicitation provisions herein shall be
deemed to be a series of separate covenants, one for each and every county of
each and every state of the United States of America and each and every
political subdivision of each and every country outside the United States of
America where this provision is intended to be effective.  The Executive agrees that damages are an
inadequate remedy for any breach of such provisions and that the Company,
shall, whether or not it is pursuing any potential remedies at law, be entitled
to seek in any court of competent jurisdiction, equitable relief in the form of
preliminary and permanent injunctions without bond or other security upon any
actual or threatened breach of either of these competition provisions.  If the Executive shall violate this Section 5,
the duration of this Section 5 automatically shall be 

 

6

 

extended as against the Executive for a period equal to the period
during which the Executive shall have been in violation of this Section 5.  The covenants contained in this Section 5
are deemed to be material and the Company is entering into this Agreement
relying on such covenants.

 

6.             Representations  and  Warranties  of  the  Executive.  The Executive, hereby represents and warrants
to the Company as follows:  (a) The
Executive has the legal capacity and unrestricted right to execute and deliver
this Agreement and to perform all of his obligations hereunder; (b) the
execution and delivery of this Agreement by the Executive and the performance
of his obligations hereunder will not violate or be in conflict with any fiduciary
or other duty, instrument, agreement, document, arrangement, or other
understanding to which Executive is a party or by which he is or may be bound
or subject; and (c) except as set forth in Exhibit A attached
hereto, the Executive is not a party to any instrument, agreement, document,
arrangement, including, but not limited to, invention assignment agreement,
confidential information agreement, non-competition agreement, non-solicitation
agreement, or other understanding with any person (other than the Company)
requiring or restricting the use or disclosure of any confidential information
or the provision of any employment, consulting or other services.

 

7.         Disclosure of
Innovations; Assignment of Ownership of Innovations; Protection of Confidential
Information. Executive hereby represents and warrants to the Company that
Executive understands that the Company is in the business of developing and
licensing finger print identification technologies, and distributing products
incorporating such technologies, to original equipment manufacturers and end
users  and that Executive may have access to
or acquire information with respect to Confidential Information (as defined
below), including software, processes and methods, development tools,
scientific, technical and/or business innovations.

 

(a)           Disclosure
of Innovations.  Executive agrees to
disclose in writing to the Company all inventions, improvements and other
innovations of any kind that Executive may make, conceive, develop or reduce to
practice, alone or jointly with others, during the term of Executive’s
employment with the Company, whether or not such inventions, improvements or
other innovations are related to and grow out of Executive’s work for the
Company and whether or not they are eligible for patent, copyright, trademark,
trade secret or other legal protection (“Innovations”).  Examples of Innovations shall include, but
are not limited to, discoveries, research, inventions, formulas, techniques,
processes, know-how, marketing plans, new product plans, production processes,
advertising, packaging and marketing techniques and improvements to computer
hardware or software.

 

(b)           Assignment
of Ownership of Innovations. 
Executive agrees that all Innovations will be the sole and exclusive
property of the Company and Executive hereby assigns all of Executive’s rights,
title or interest in the Innovations and in all related patents, copyrights,
trademarks, trade secrets, rights of priority and other proprietary rights to
the Company.  At the Company’s request
and expense, during and after the period of Executive’s employment 

 

7

 

with the Company, Executive will assist and cooperate with the Company
in all respects and will execute documents, and, subject to Executive’s
reasonable availability, give testimony and take further acts requested by the
Company to obtain, maintain, perfect and enforce for the Company patent,
copyright, trademark, trade secret and other legal protection for the
Innovations.  Executive hereby appoints
an authorized officer of the Company as Executive’s attorney-in-fact to execute
documents on his behalf for this purpose. 
Executive has attached hereto as Exhibit B a list of
Innovations as of the date hereof which belong to Executive and which are not
assigned to the Company hereunder (the “Prior Innovations”), or, if no such
list is attached, Executive represents that there are no Prior Innovations.

 

(c)           Protection of
Confidential Information of the Company. 
Executive understands that Executive’s work as an Executive of the
Company creates a relationship of trust and confidence between Executive and
the Company.  During and after the period
of Executive’s employment with the Company, Executive will not use or disclose
or allow anyone else to use or disclose any “Confidential Information” (as
defined below) relating to the Company, its products, services, suppliers or
customers except as may be necessary in the performance of Executive’s work for
the Company or as may be specifically authorized in advance by appropriate
officers of the Company. “Confidential Information” shall include, but not be
limited to, information consisting of research and development, patents,
trademarks and copyrights and applications thereto, technical information,
computer programs, software, methodologies, innovations, software tools,
know-how, knowledge, designs, drawings, specifications, concepts, data,
reports, processes, techniques, documentation, pricing, marketing plans,
customer and prospect lists, trade secrets, financial information, salaries,
business affairs, suppliers, profits, markets, sales strategies, forecasts,
Executive information and any other information not available to the general
public, whether written or oral, which Executive knows or has reason to know
the Company would like to treat as confidential for any purpose, such as
maintaining a competitive advantage or avoiding undesirable publicity.  Executive will keep Confidential Information
secret and will not allow any unauthorized use of the same, whether or not any
document containing it is marked as confidential.  These restrictions, however, will not apply
to Confidential Information that has become known to the public generally
through no fault or breach of Executive’s or that the Company regularly gives
to third parties without restriction on use or disclosure.

 

8.             Work Made For Hire.

 

(a)           Work
Made For Hire. Executive further recognizes and understands that Executive’s
duties at the Company may include the preparation of materials, including
without limitation written or graphic materials, and that any such materials
conceived or written by Executive shall be done as “work made for hire” as
defined and used in the Copyright Act of 1976, 17 U.S.C. §§ 1 et  seq.  In the event of publication of such
materials, Executive understands that since the work is a “work made for hire”,
the Company will solely retain and own all rights in said materials, including
right of copyright.  In the event that
any of such works shall be deemed by a court of competent jurisdiction not to
be a “work made for hire,” this Agreement 

 

8

 

shall operate as an irrevocable assignment by Executive to the Company
of all right, title and interest in and to such works, including, without
limitation, all worldwide copyright interests therein, in perpetuity.  The fact that such copyrightable works are
created by Executive outside of the Company’s facilities or other than during
Executive’s working hours with the Company shall not diminish the Company’s
right with respect to such works which otherwise fall within this
paragraph.  Executive agrees to execute
and deliver to the Company such further instruments or documents as may be
requested by the Company in order to effectuate the purposes of this paragraph.

 

(b)           Disclosure of Works and
Inventions/Assignment of Patents.  In
consideration of the promises set forth herein, Executive agrees to disclose
promptly to the Company, or to such person whom the Company may expressly designate
for this specific purpose (its “Designee”), any and all works, inventions,
discoveries and improvements authored, conceived or made by Executive during
the period of employment and related to the business or activities of the
Company, and Executive hereby assigns and agrees to assign all of Executive’s
interest in the foregoing to the Company or to its Designee.  Executive agrees that, whenever he is
requested to do so by the Company, Executive shall execute any and all
applications, assignments or other instruments which the Company shall deem
necessary to apply for and obtain Letters Patent or Copyrights of the United
States or any foreign country or to otherwise protect the Company’s interest
therein.  Such obligations shall continue
beyond the termination or nonrenewal of Executive’s employment or service with
respect to any works, inventions, discoveries and/or improvements that are
authored, conceived of, or made by Executive during the period of Executive’s
employment or service, and shall be binding upon Executive’s successors,
assigns, executors, heirs, administrators or other legal representatives.

 

9.             Company  Property.  All records, files, lists, including computer
generated lists, drawings, documents, software, documents, equipment, models,
binaries, object modules, libraries, source code and similar items relating to
the Company’s business that the Executive shall prepare or receive from the
Company and all Confidential Information shall remain the Company’s sole and
exclusive property (“Company Business Property”).  Upon termination of this Agreement, the
Executive shall promptly return to the Company all property of the Company in
his possession, including Company Business Property.  The Executive further represents that he will
not copy or cause to be copied, print out, or cause to be printed out any
Company Business Property other than as specifically authorized and required in
the performance of the Executive’s duties. 
The Executive additionally represents that, upon termination of his employment
with the Company, he will not retain in his possession any such Company
Business Property; provided, however, that the Executive shall be
entitled to inspect, copy and retain copies of documents in any personnel file
relating to his employment which is maintained by the Company.

 

10.           Cooperation.  The Executive and Company agree that  during 
the term of Executive’s employment they shall, at the request of the
other Party, render all assistance and perform all lawful acts that each Party
considers necessary or advisable in connection with any 

 

9

 

litigation involving either Party or any director, officer, Executive,
shareholder, agent, representative, consultant, client, or vendor of the
Company.  Executive shall be entitled to
all protections afforded officers, agents and directors under the Company’s
Certificate of Incorporation and Bylaws. 
The Company shall maintain a Directors and Officers Liability Insurance
Policy.

 

11.           Employment Dispute Settlement
Procedure/Waiver of Rights. The Executive and the Company each agree that,
in the event either party (or its representatives, successors or assigns)
brings an action in a court of competent jurisdiction relating to the Executive’s
recruitment, employment with, or termination of employment from the Company,
each party in such action agrees to waive his, her or its right to a trial by
jury, and further agrees that no demand, request or motion will be made for
trial by jury.

 

The parties hereto
further agree that, in the event that either seeks relief in a court of
competent jurisdiction for a dispute covered by this Agreement, any other
Agreement between the Executive and the Company or which relates to the
Executive’s recruitment, employment with, or termination of employment from the
Company, the defendant or third-party defendant in such action may, at any time
within sixty (60) days of the service of the complaint, third-party complaint
or cross-claim upon such party, at his, her or its option, require all or part
of the dispute to be arbitrated by one arbitrator in accordance with the rules of
the American Arbitration Association. The parties agree that the option to
arbitrate any dispute is governed by the Federal Arbitration Act.  The parties understand and agree that, if the
other party exercises his, her or its option, any dispute arbitrated will be
heard solely by the arbitrator, and not by a court.  Judgment upon the award rendered, however,
may be entered in any court of competent jurisdiction.  The cost of such arbitration shall be borne
equally by the parties.

 

This dispute
resolution agreement will cover all matters directly or indirectly related to
the Executive’s recruitment, employment or termination of employment by the
Company; including, but not limited to, claims involving laws against
discrimination whether brought under federal and/or state law and/or local law,
and/or claims involving co-Executives but excluding Worker’s Compensation
Claims.  Nothing contained in this Section 11
shall limit the right of the Company to enforce by court injunction or other
equitable relief the Executive’s obligations under Sections 5, 7, 8 and 9
hereof.

 

The right to a trial, and
to a trial by jury, is of value.

 

THE EXECUTIVE MAY WISH
TO CONSULT AN ATTORNEY PRIOR TO SIGNING THIS AGREEMENT.  IF SO, THE EXECUTIVE SHOULD TAKE A COPY OF
THIS AGREEMENT WITH HIM.  HOWEVER, THE
EXECUTIVE WILL NOT BE OFFERED EMPLOYMENT UNTIL THIS AGREEMENT IS SIGNED AND
RETURNED TO EMPLOYER.

 

10

 

12.           Choice of Law and Jurisdiction.
This Agreement shall be construed, interpreted and the rights of the parties
determined in accordance with the laws of the Commonwealth of
Massachusetts.  Each of the parties
hereto hereby irrevocably consents and submits to the exclusive jurisdiction of
the state courts of the Commonwealth of Massachusetts, and of the United States
District Court located in Boson, Massachusetts in connection with any suit,
action, or other proceeding concerning this Agreement or enforcement of
Sections 5, 7, 8 and 9 hereof.  The
Executive waives and agrees not to assert any defense that the court lacks
jurisdiction, venue is improper, inconvenient forum or otherwise.  The Executive waives the right to a jury
trial and agrees to accept service of process by certified mail at the
Executive’s last known address.

 

13.           Successors and Assigns.  Neither this Agreement, nor any of the
Executive’s rights, powers, duties or obligations hereunder, may be assigned by
the Executive.  This Agreement shall be
binding upon and inure to the benefit of the Executive and his heirs and legal
representatives and the Company and its successors.  Successors of the Company shall include,
without limitation, any company or companies, individuals, groups, associations,
partnerships, firm, venture or other entity or party acquiring, directly or
indirectly, all or substantially all of the assets of the Company, whether by
merger, consolidation, purchase, lease or otherwise.  Any such successor referred to in this paragraph
shall thereafter be deemed “the Company” for the purpose hereof.  All covenants and restrictions upon the
Executive hereunder, including, but not limited to Sections 5, 7, 8 and 9
hereof, are specifically assignable by the Company.

 

14.           Waiver. Any waiver or consent
from the Company with respect to any term or provision of this Agreement or any
other aspect of the Executive’s conduct or employment shall be effective only
in the specific instance and for the specific purpose for which given and shall
not be deemed, regardless of frequency given, to be a further or continuing
waiver or consent.  The failure or delay
of the Company at any time or times to require performance of, or to exercise
any of its powers, rights or remedies with respect to any term or provision of
this Agreement or any other aspect of the Executive’s conduct or employment in
no manner (except as otherwise expressly provided herein) shall affect the
Company’s right at a later time to enforce any such term or provision.

 

15.           Notices.  All notices, requests, demands, and other
communications hereunder must be in writing and shall be deemed to have been
duly given if delivered by hand or mailed within the continental United States
by first class, registered mail, return receipt requested, postage and registry
fees prepaid, to the applicable party and addressed as follows:

 

11

 

	
  (a)

  	
  If to the Company:

  
	
   

  	
   

  
	
   

  	
  BIO-key International, Inc.

  
	
   

  	
  3349 Highway 138 Building D Suite B

  
	
   

  	
  Wall, NJ 07719

  
	
   

  	
  Attn: Chairman, Board of Directors

  
	
   

  	
   

  
	
  (b)

  	
  If to the Executive:

  
	
   

  	
   

  
	
   

  	
  Michael W. DePasquale

  
	
   

  	
  704 Michael Drive

  
	
   

  	
  Toms River, NJ 08753

  

 

16.           Construction of Agreement.

 

(a)           Severability.  In the event that any one or more of the
provisions of this Agreement shall be held to be invalid, illegal or
unenforceable, the validity, legality or enforceability of the remaining
provisions shall not in any way be affected or impaired thereby.

 

(b)           Headings.  The descriptive headings of the several
paragraphs of this Agreement are inserted for convenience of reference only and
shall not constitute a part of this Agreement.

 

17.           Entire Agreement and Amendments.  This Agreement, including all Exhibits which
shall form parts hereof, contains the entire agreement of the parties
concerning the Executive’s employment and all promises, representations,
understandings, arrangements and prior agreements on such subject are merged
herein and superseded hereby.  The
provisions of this Agreement may not be amended, modified, repealed, waived,
extended or discharged except by an agreement in writing signed by the party
against whom enforcement of any amendment, modification, repeal, waiver,
extension or discharge is sought.  No
person acting other than pursuant to a resolution of the Board of Directors
shall have authority on behalf of the Company to agree to amend, modify,
repeal, waive, extend or discharge any provision of this Agreement or anything
in reference thereto or to exercise any of the Company’s rights to terminate or
to fail to extend this Agreement.

 

18.           Survival.  The Executive’s obligations under
Paragraphs 5, 7, 8 and 9 shall survive and continue pursuant to the terms and
conditions of this Agreement following specific termination.

 

19.           Understanding. The Executive
represents and agrees that he fully understands his rights to discuss all
aspects of this Agreement with his private attorney, that to the extent he
desires, he availed himself of this right, that he has carefully read and fully
understands all of the provisions of this Agreement, that he is competent to
execute this Agreement, that his decision to execute this Agreement has not
been obtained by any duress and that he freely and voluntarily 

 

12

 

enters into this Agreement, and that he has read this document in its
entirety and fully understands the meaning, intent, and consequences of this
Agreement.

 

20.           Counterparts.  This Agreement may be executed in any number
of counterparts, each of which shall be deemed an original, and all of which
together shall constitute one and the same instrument.

 

21.           Injunctive  Relief.
The Executive hereby agrees and acknowledges that in the event of a breach or
threatened breach of this Agreement by the Executive, the Company may suffer
irreparable harm and monetary damages alone would not adequately compensate the
Company.  Accordingly, the Company will
therefore be entitled to injunctive relief to enforce this Agreement.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK]

 

13

 

IN
WITNESS WHEREOF,
the Company has caused this Agreement to be executed and attested by its duly
authorized officers, and the Executive has set his hand, all as of the day and
year first above written.

 

 

	
   

  	
  BIO-KEY INTERNATIONAL,
  INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  Name: Thomas J.
  Colatosti

  
	
   

  	
   

  	
  Title:   Chairman of the Board of Directors

  
	
   

  	
   

  
	
   

  	
  EXECUTIVE

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Michael W.
  DePasquale

  

 

14ex10one.htm

 

 

 

 

 

NOTE AND WARRANT PURCHASE AGREEMENT

THIS NOTE AND WARRANT PURCHASE AGREEMENT, dated as of March 22, 2010 (this “Agreement”), is entered into by and between RADIENT PHARMACEUTICALS CORPORATION, a Delaware corporation with headquarters located at 2492 Walnut Ave., Suite 100 Tustin, CA 92780-6953 (the “Company”), and ISP Holdings, LLC, a Utah limited liability company (the “Buyer”).

W I T N E S S E T H:

WHEREAS, the Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration for offers and sales to accredited investors afforded, inter alia, by Rule 506 under Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “1933 Act”), and/or Section 4(2) of the 1933 Act; and

 

WHEREAS, the Buyer wishes to acquire from the Company, and the Company desires to issue and sell to the Buyer, (i) the Note (as defined below), which Note will be convertible into shares of Common Stock, $0.001 par value, of the Company (the “Common Stock”), and (ii) the Warrant (as defined hereafter), which will be exercisable for shares of Common Stock, upon the terms and subject to the conditions of the Note, the Warrant, this Agreement and the other Transaction Documents (as defined below).

 

NOW THEREFORE, in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1.           CERTAIN DEFINITIONS.   As used herein, each of the following terms has the meaning set forth below, unless the context otherwise requires:

“Affiliate” means, with respect to a specific Person referred to in the relevant provision, another Person who or which controls or is controlled by or is under common control with such specified Person.

“Buyer’s Counsel” means Bennett Tueller Johnson & Deere, P.C.

 

“Buyer Control Person” means each director, executive officer, promoter, and such other Persons as may be deemed in control of the Buyer pursuant to Rule 405 under the 1933 Act or Section 20 of the 1934 Act (as defined below).

“Certificate of Incorporation” means the certificate of incorporation, articles of incorporation or other charter document (howsoever denominated) of the Company, as amended to date.

“Closing Date” means the date of the closing of the purchase and sale of the Securities.

 “Company Control Person” means each director, executive officer, promoter, and such other Persons as may be deemed in control of the Company pursuant to Rule 405 under the 1933 Act or Section 20 of the 1934 Act.

“Company Counsel” means Leser, Hunter, Taubman & Taubman.

 

 

  

1

  

 

“Company’s SEC Documents” means the Company’s filings on the SEC’s EDGAR system which are listed on Annex I annexed hereto, to the extent available on EDGAR or otherwise provided to the Buyer as indicated on said Annex I.

“Conversion Date” means the date a Holder submits a Notice of Conversion, as provided in the Note.

“Conversion Shares” means the shares of Common Stock issuable upon conversion of the Note and/or in payment of accrued interest, as contemplated in the Note.

“Converting Holder” means the Holder of the Note, who or which has submitted a Notice of Conversion (as contemplated by the Note) and/or Holder of the Warrant who or which has submitted a Notice of Exercise.

“Delivery Date” has the meaning ascribed to it, as may be relevant in the Note (with respect to Conversion Shares).

“Disbursement Instructions” means the Net Purchase Price Disbursement Instructions provided by the Company substantially in the form attached hereto as Annex IIIand incorporated herein by this reference.

“Disclosure Annex” means Annex II to this Agreement; provided, however, that the Disclosure Annex shall be arranged in sections corresponding to the identified Sections of this Agreement, but the disclosure in any such section of the Disclosure Annex shall qualify other provisions in this Agreement to the extent that it would be readily apparent to an informed reader from a reading of such section of the Disclosure Annex that it is also relevant to other provisions of this Agreement.

“Holder” means the Person holding the relevant Securities at the relevant time.

“Last Audited Date” means December 31, 2008.

 

“Material Adverse Effect” means an event or combination of events, which individually or in the aggregate, would reasonably be expected to (x) adversely affect the legality, validity or enforceability of the Purchased Securities or any of the Transaction Documents, (y)  have or result in a material adverse effect on the results of operations, assets, or financial condition of the Company and its subsidiaries, taken as a whole, or (z) adversely impair the Company’s ability to perform fully on a timely basis its material obligations under any of the Transaction Documents or the transactions contemplated thereby.

“Maturity Date” has the meaning ascribed to it in the Note.

“Person” means any living person or any entity, such as, but not necessarily limited to, a corporation, partnership or trust.

 

“Principal Trading Market” means (a) the NYSE Amex, (b) the New York Stock Exchange, (c) the Nasdaq Global Market, (d) the Nasdaq Capital Market, or (e) the Nasdaq OTC Bulletin Board, or (f) such other market on which the Common Stock is principally traded at the relevant time, but shall not include the “pink sheets.”

 

“Regular Trading Day” means the regular trading hours of a Trading Day on the Principal Trading Market shall be open for business (as of the date of this Agreement, such hours are, for most Trading Days, approximately 9:00 or 9:30AM to approximately 4PM Eastern Time; provided, however, that certain Trading Days may have shorter regular trading hours; and provided, further, that the regular trading hours may be subsequently changed for the Principal Trading Market).

 

 

 

  

2

  

 

“Reporting Service” means Bloomberg LP or if that service is not then reporting the relevant information regarding the Common Stock, a comparable reporting service of national reputation selected by a Majority in Interest of the Holders.

 “Rule 144” means (i) Rule 144 promulgated under the 1933 Act or (ii) any other similar rule or regulation of the SEC that may at any time permit Holder to sell securities of the Company to the public without registration under the 1933 Act.

“Securities” means the Purchased Securities (as defined in Section 2(a)(iii) below) and the Shares.

“Shares” means the shares of Common Stock representing any or all of the Conversion Shares and/or the Warrant Shares (as defined hereafter).

“State of Incorporation” means New Jersey.

“Subsidiary” means, as of the relevant date, any subsidiary of the Company (whether or not included in the Company’s SEC Documents) whether now existing or hereafter acquired or created.

“Trading Day” means any day during which the Principal Trading Market shall be open for business.

“Transaction Documents” means (i) this Agreement, (ii) the Note, (iii) the Disclosure Annex, (iv) the Warrant (as defined hereafter), (v) the Registration Rights Agreement substantially in the form attached hereto as Annex IV, (vi) the Consent to Entry of Judgment by Confession (the “Confession of Judgment”) substantially in the form attached hereto as Annex V, (vii) the Unanimous Written Consent of the Board substantially in the form attached hereto as Annex VI, (viii) the Officer Certificate substantially in the form attached hereto as Annex VII, and (ix) all other certificates, documents, agreements, resolutions and instruments delivered to any party under or in connection with this Agreement.

 

“Transfer Agent” means, at any time, the transfer agent for the Company’s Common Stock.

“Warrant Shares” means the shares of Common Stock issuable upon exercise of the Warrant.

2.           AGREEMENT TO PURCHASE; NET PURCHASE PRICE; CLOSING.

a.           Purchase.

(i)           Subject to the terms and conditions of this Agreement and the other Transaction Documents, the undersigned Buyer hereby agrees to loan to the Company the Net Purchase Price (as defined hereafter) set forth on the Buyer’s signature page of this Agreement.

 

               (ii)   The obligation to repay the loan from the Buyer shall be evidenced by the Company’s issuance of a Convertible Promissory Note to the Buyer in the principal amount of $925,000.00 substantially in the form attached hereto as Annex VIII (the “Note”).  The Note shall provide for a Conversion Price (as defined in the Note), which price may be adjusted from time to as provided in the Note.

 

 

 

  

3

  

 

(iii)  As additional consideration for the Net Purchase Price, the Company shall also issue to the Buyer a warrant to purchase 1,100,000 shares of the Common Stock substantially in the form attached hereto as Annex IX (the “Warrant,” and together with the Note, the “Purchased Securities”).

b.           Closing; Delivery of Transaction Documents. The sale and purchase of the Purchased Securities shall take place at a closing (the “Closing”) to be held at the offices of the Buyer on the Closing Date.  At the Closing, the Company will deliver to the Buyer the Transaction Documents against receipt by the Company of the Net Purchase Price.

 

c.           Net Purchase Price.  The Note carries a twenty percent (20%) original issue discount (“OID”).  In addition, the Company agrees to pay $200,000 to the Buyer to cover the Buyer’s legal fees, accounting costs, due diligence, monitoring and other transaction costs incurred in connection with the purchase and sale of the Purchased Securities (the “Transaction Expenses”).  The Transaction Expenses shall be withheld by the Buyer at the Closing.  Accordingly, the “Net Purchase Price” shall be $540,000.00, computed as follows: $925,000.00 less the OID less the Transaction Expenses.

d.           Method of Payment.  Payment of the Net Purchase Price shall be made to the Company in immediately available funds of the United States as provided in the Disbursement Instructions.

3.           BUYER REPRESENTATIONS AND WARRANTIES.  The Buyer represents and warrants to, and covenants and agrees with, the Company, as of the date hereof and as of the Closing Date, as follows:

 

a.           Without limiting Buyer’s right to sell the Securities pursuant to an effective registration statement or otherwise in compliance with the 1933 Act, the Buyer is purchasing the Securities for its own account for investment only and not with a view towards the public sale or distribution thereof and not with a view to or for sale in connection with any distribution thereof.

b.           All subsequent offers and sales of the Securities by the Buyer shall be made pursuant to registration of the Securities under the 1933 Act or pursuant to an exemption from such registration.

c.           The Buyer understands that the Securities are being offered and sold to it in reliance on specific exemptions from the registration requirements of the 1933 Act and state securities laws and that the Company is relying upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of the Buyer to acquire the Securities.

 

d.           If the Buyer is an individual, then the Buyer resides in the state or province identified in the address of the Buyer set forth on the Buyer’s signature page to this Agreement.  If the Buyer is a partnership, corporation, limited liability company or other entity, then the office or offices of the Buyer in which its principal place of business is the address or addresses of the Buyer set forth on the Buyer’s signature page to this Agreement.

e.           The Buyer understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities.

 

f.           The Transaction Documents to which the Buyer is a party, and the transactions contemplated hereby and thereby, have been duly and validly authorized by the Buyer.  This Agreement has been executed and delivered by the Buyer, and this Agreement is, and each of the other Transaction Documents to which the Buyer is a party, when executed and delivered by the Buyer (if necessary), will be valid and binding obligations of the Buyer enforceable in accordance with their respective terms, subject as to enforceability to general principles of equity and to bankruptcy, insolvency, moratorium and other similar laws affecting the enforcement of creditors’ rights generally.

 

 

 

  

4

  

 

g.           The Buyer is an “accredited investor” as that term is defined in Rule 501 of the General Rules and Regulations under the 1933 Act.

 

4.           COMPANY REPRESENTATIONS AND WARRANTIES.   The Company represents and warrants to the Buyer as of the date hereof and as of the Closing Date that, except as otherwise provided in the Disclosure Annex:

 

a.           Rights of Others Affecting the Transactions.  Except for the right of participation (the “Participation Rights”) under Section 4.11 of the Securities Purchase Agreement dated as of November 30, 2009 with Whalehaven LP and Alpha Capital Anstalt (the “Participation Rights Holders”), there are no preemptive rights of any stockholder of the Company, as such, to acquire the Purchased Securities or the Shares.  No other party has a currently exercisable right of first refusal which would be applicable to any or all of the transactions contemplated by the Transaction Documents.  The Company has undertaken all actions, and otherwise complied with all requirements of, required by the Participation Rights and has received written confirmation that the Participation Rights Holders will neither participate in nor object to the transactions contemplated hereby, as more fully set forth on the Officer Certificate.

b.           Status.  The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Incorporation and has the requisite corporate power to own its properties and to carry on its business as now being conducted.  The Company is duly qualified as a foreign corporation to do business and is in good standing in each jurisdiction where the nature of the business conducted or property owned by it makes such qualification necessary, other than those jurisdictions in which the failure to so qualify would not have or result in a Material Adverse Effect.  The Company has registered its stock under Section 12(g) of the Securities and Exchange Act of 1934, as amended (the “1934 Act”), and is obligated to file reports pursuant to Section 13 or Section 15(d) of the 1934 Act.   The Company has taken no action designed to terminate, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the 1934 Act nor has the Company received any notification that the SEC is contemplating terminating such registration.  The Common Stock is quoted on the Principal Trading Market.  The Company has received no notice, either oral or written, with respect to the continued eligibility of the Common Stock for quotation on the Principal Trading Market, and the Company has maintained all requirements on its part for the continuation of such quotation. The Company has not, in the twelve (12) months preceding the date hereof, received notice from the Principal Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Principal Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.

c.           Authorized Shares.

 

(i)           The authorized capital stock of the Company consists of (x) 100,000,000 shares of Common Stock, of which approximately 24,700,000 undiluted shares and approximately 41,115,000 (fully diluted) are outstanding as of the March 15, 2010. Of the outstanding shares of Common Stock, approximately 250,000 shares are beneficially owned by Affiliates of the Company as of March 15, 2010.

 

(ii)           Other than as set forth in the Company’s SEC Documents and the agreements referred to with holders of the Company’s indebtedness as described in the Preliminary Proxy Statement filed with the SEC on February 1, 2010 (the “Preliminary Proxy Statement”), there are no outstanding securities which are convertible into or exchangeable for shares of Common Stock, whether such conversion is currently exercisable or exercisable only upon some future date or the occurrence of some event in the future.

 

 

 

  

5

  

 

(iii)           All issued and outstanding shares of Common Stock have been duly authorized and validly issued and are fully paid and non-assessable.  Except for all of the issuances as proposed in the Preliminary Proxy Statement, after considering all other commitments that may require the issuance of Common Stock, the Company has sufficient authorized and unissued shares of Common Stock as may be necessary to effect the issuance of the Shares on the Closing Date, were the Note fully converted, and the Warrant fully exercised, on that date.

 

(iv)           The Shares have been duly authorized by all necessary corporate action on the part of the Company, and, when issued on conversion of, or in payment of interest on the Note, in each case in accordance with their respective terms, will have been duly and validly issued, fully paid and non-assessable, free from all taxes, liens, claims, pledges, mortgages, restrictions, obligations, security interests and encumbrances of any kind, nature and description, and will not subject the Holder thereof to personal liability by reason of being such Holder.

 

d.           Transaction Documents and Stock.  This Agreement and each of the other Transaction Documents, and the transactions contemplated hereby and thereby, have been duly and validly authorized by the Company.  This Agreement has been duly executed and delivered by the Company and this Agreement is, and the Note, and each of the other Transaction Documents, when executed and delivered by the Company (if necessary), will be, valid and binding obligations of the Company enforceable in accordance with their respective terms, subject as to enforceability to general principles of equity and to bankruptcy, insolvency, moratorium, and other similar laws affecting the enforcement of creditors’ rights generally.

 

e.           Non-contravention.  The execution and delivery of this Agreement and each of the other Transaction Documents by the Company, the issuance of the Securities in accordance with the terms hereof, and the consummation by the Company of the other transactions contemplated by this Agreement, the Note, and the other Transaction Documents do not and will not conflict with or result in a breach by the Company of any of the terms or provisions of, or constitute a default under (i) the Certificate of Incorporation or by-laws of the Company, each as currently in effect, (ii) any indenture, mortgage, deed of trust, or other material agreement or instrument to which the Company is a party or by which it or any of its properties or assets are bound, including any listing agreement for the Common Stock except as herein set forth, or (iii) to its knowledge, any existing applicable law, rule, or regulation or any applicable decree, judgment, or order of any court, United States federal or state regulatory body, administrative agency, or other governmental body having jurisdiction over the Company or any of its properties or assets, except such conflict, breach or default which would not have or result in a Material Adverse Effect.

 

f.           Approvals.  No authorization, approval or consent of any court, governmental body, regulatory agency, self-regulatory organization, or stock exchange or market or the stockholders of the Company is required to be obtained by the Company for the issuance and sale of the Securities to the Buyer as contemplated by this Agreement, except the approval of the NYSE Amex to list the Conversion Shares or the Warrant Shares, and the approval of the NYSE Amex and the Company’s stockholders to issue a number of Shares in excess of 19.99% of the outstanding shares of Common Stock of the Company as of the Closing Date (the “19.99% Cap”) .

 

g.           Filings; Financial Statements.  None of the Company’s SEC Documents contained, at the time they were filed, any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances under which they were made, not misleading.  Since December 31, 2006, the Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company with the SEC under the 1934 Act on timely basis or has received a valid extension of such time of filing and has filed any such SEC Document prior to the expiration of any such extension.  As of their respective dates, the financial statements of the Company included in the Company’s SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules 

 

 

  

6

  

 

 

and regulations of the SEC with respect thereto.  Such financial statements have been prepared in accordance with generally accepted accounting principles, consistently applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the Note thereto, or (ii) in the case of unaudited interim statements, to the extent they may exclude footnote or may be condensed or summary statements) and fairly present in all material respects the financial position of the Company as of the dates thereof and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments).  No other information provided by or on behalf of the Company to the Buyer which is not included in the Company’s SEC Documents, including, without limitation, information referred to in this Agreement, contains any untrue statement of a material fact or omits to state any material fact necessary in order to make the statements therein, in the light of the circumstance under which they are or were made, not misleading.

 

h.           Absence of Certain Changes.  Since the Last Audited Date, there has been no Material Adverse Effect, except as disclosed in the Company’s SEC Documents. Since the Last Audited Date, except as provided in the Company’s SEC Documents, the Company has not (i) incurred or become subject to any material liabilities (absolute or contingent) except liabilities incurred in the ordinary course of business consistent with past practices; (ii) discharged or satisfied any material lien or encumbrance or paid any material obligation or liability (absolute or contingent), other than current liabilities paid in the ordinary course of business consistent with past practices; (iii) declared or made any payment or distribution of cash or other property to stockholders with respect to its capital stock, or purchased or redeemed, or made any agreements to purchase or redeem, any shares of its capital stock; (iv) sold, assigned or transferred any other material tangible assets, or canceled any material debts owed to the Company by any third party  or material claims of the Company against any third party, except in the ordinary course of business consistent with past practices; (v) waived any rights of material value, whether or not in the ordinary course of business, or suffered the loss of any material amount of existing business; (vi) made any increases in employee compensation, except in the ordinary course of business consistent with past practices; or (vii) experienced any material problems with labor or management in connection with the terms and conditions of their employment.

 

i.           Full Disclosure.  There is no fact known to the Company or that the Company should know after having made all reasonable inquiries (other than conditions known to the public generally or as disclosed in the Company’s SEC Documents) that has not been disclosed in writing to the Buyer that would reasonably be expected to have or result in a Material Adverse Effect.

 

j.           Absence of Litigation.  There is no action, suit, proceeding, inquiry or investigation before or by any court, public board or body pending or, to the knowledge of the Company, threatened against or affecting the Company before or by any governmental authority or non-governmental department, commission, board, bureau, agency or instrumentality or any other person, wherein an unfavorable decision, ruling or finding would have a Material Adverse Effect or which would adversely affect the validity or enforceability of, or the authority or ability of the Company to perform its obligations under, any of the Transaction Documents.  The Company is not aware of any valid basis for any such claim that (either individually or in the aggregate with all other such events and circumstances) could reasonably be expected to have a Material Adverse Effect. There are no outstanding or unsatisfied judgments, orders, decrees, writs, injunctions or stipulations to which the Company is a party or by which it or any of its properties is bound, that involve the transaction contemplated herein or that, alone or in the aggregate, could reasonably be expected to have a Material Adverse Effect.

 

 

 

  

7

  

 

k.           Absence of Events of Default.  Except as set forth on Annex II  or in Section 3(e) hereof, no Event of Default (or its equivalent term), as defined in the respective agreement to which the Company or its Subsidiary is a party, and no event which, with the giving of notice or the passage of time or both, would become an Event of Default (or its equivalent term) (as so defined in such agreement), has occurred and is continuing, which would have a Material Adverse Effect.

 

l.           Absence of Certain Company Control Person Actions or Events.  Other than as set forth in the Company’s SEC Documents, none of the following has occurred during the past five (5) years with respect to a Company Control Person:

 

(i) A petition under the federal bankruptcy laws or any state insolvency law was filed by or against, or a receiver, fiscal agent or similar officer was appointed by a court for the business or property of such Company Control Person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing;

(ii) Such Company Control Person was convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);

 

(iii) Such Company Control Person was the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:

(A) acting, as an investment advisor, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, any other Person regulated by the Commodity Futures Trading Commission (“CFTC”) or engaging in or continuing any conduct or practice in connection with such activity;

(B) engaging in any type of business practice; or

(C) engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of federal or state securities laws or federal commodities laws;

 

(iv) Such Company Control Person was the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any federal or state authority barring, suspending or otherwise limiting for more than 60 days the right of such Company Control Person to engage in any activity described in paragraph (3) of this item, or to be associated with Persons engaged in any such activity; or

 

(v) Such Company Control Person was found by a court of competent jurisdiction in a civil action or by the CFTC or SEC to have violated any federal or state securities law, and the judgment in such civil action or finding by the CFTC or SEC has not been subsequently reversed, suspended, or vacated.

 

m.           No Undisclosed Liabilities or Events.  The Company has no liabilities or obligations other than those disclosed on Annex II or in the Transaction Documents or the Company’s SEC Documents or those incurred in the ordinary course of the Company’s business since the Last Audited Date, or which individually or in the aggregate, do not or would not have a Material Adverse Effect.  No event or circumstance has occurred or exists with respect to the Company or its properties, business, operations, condition (financial or otherwise), or results of operations, which, under applicable law, rule or regulation, requires public disclosure or announcement prior to the date hereof by the Company but which has not been so publicly announced or disclosed.  There are no proposals currently under consideration or currently anticipated to be under consideration by the Board of Directors or the executive 

 

 

  

8

  

 

 

officers of the Company which proposal would (x) change the Certificate of Incorporation or by-laws of the Company, each as currently in effect, with or without stockholder approval, which change would reduce or otherwise adversely affect the rights and powers of the stockholders of the Common Stock or (y) materially or substantially change the business, assets or capital of the Company, including its interests in subsidiaries.

n.           No Integrated Offering.  Neither the Company nor any of its Affiliates nor any Person acting on its or their behalf has, directly or indirectly, made any offer or sales of any security or solicited any offers to buy any security under circumstances that would eliminate the availability of the exemption from registration under Regulation D in connection with the offer and sale of the Securities as contemplated hereby.

o.           Dilution.  Each of the Company and its executive officers and directors is aware that the number of shares issuable on conversion of the Note, or pursuant to the other terms of the Transaction Documents may have a dilutive effect on the ownership interests of the other stockholders (and Persons having the right to become stockholders) of the Company.  The Company specifically acknowledges that its obligation to issue the Conversion Shares upon conversion of the Note is binding upon the Company and enforceable regardless of the dilution such issuance may have on the ownership interests of other stockholders of the Company, and the Company will honor such obligations, including honoring every Notice of Conversion (as contemplated by the Note), unless the Company is subject to an injunction (which injunction was not sought by the Company) prohibiting the Company from doing so.

 

p.           Fees to Brokers, Placement Agents and Others.  Other than a finder’s fee of $30,000 payable to Galileo Asset Management, S.A. (“Galileo”), which the Company shall be solely responsible to pay, the Company has taken no action which would give rise to any claim by any Person for brokerage commission, placement agent or finder’s fees or similar payments by Buyer relating to this Agreement or the transactions contemplated hereby.  Except for such fees arising as a result of any agreement or arrangement entered into by the Buyer without the knowledge of the Company (a “Buyer’s Fee”), Buyer shall have no obligation with respect to such fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this paragraph that may be due in connection with the transactions contemplated hereby.  The Company shall indemnify and hold harmless each of Buyer, its employees, officers, directors, agents, and partners, and their respective Affiliates, from and against all claims, losses, damages, costs (including the costs of preparation and attorney’s fees) and expenses suffered in respect of any such claimed or existing fees (other than a Buyer’s Fee).

 

q.           Disclosure.  All information relating to or concerning the Company set forth in the Transaction Documents or in the Company’s public filings with the SEC is true and correct in all material respects and the Company has not omitted to state any material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading.  No event or circumstance has occurred or exists with respect to the Company or its business, properties, prospects, operations or financial conditions, which under applicable law, rule or regulation, requires public disclosure or announcement by the Company.

 

r.           Confirmation.  The Company agrees that, if, to the knowledge of the Company, any events occur or circumstances exist prior to the payment of the Net Purchase Price to the Company which would make any of the Company’s representations or warranties set forth herein materially untrue or materially inaccurate as of such date, the Company shall immediately notify the Buyer in writing prior to such date of such fact, specifying which representation, warranty or covenant is affected and the reasons therefor.

 

 

 

  

9

  

 

 

s.           Title. The Company and the Company’s subsidiaries, if applicable, own and have good and marketable title in fee simple absolute to, or a valid leasehold interest in, all their respective real properties and good title to their other respective assets and properties, subject to no liens except as have been disclosed to the Investor.

 

t.           Intellectual Property.

 

(i) Ownership.  The Company owns or possesses or can obtain on commercially reasonable terms sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses (software or otherwise), information, processes and similar proprietary rights (“Intellectual Property”) necessary to the business of the Company as presently conducted, the lack of which could reasonably be expected to have a Material Adverse Effect.  Except for agreements with its own employees or consultants, standard end-user license agreements, support/maintenance agreements and agreements entered in the ordinary course of the Company’s business, all of which have been made available for review by the Investor, there are no outstanding options, licenses or agreements relating to the Intellectual Property, and the Company is not bound by or a party to any options, licenses or agreements with respect to the Intellectual Property of any other person or entity.  The Company has not received any written communication alleging that the Company has violated or, by conducting its business as currently conducted, would violate any of the Intellectual Property of any other person or entity, nor is the Company aware of any basis therefor.  The Company is not obligated to make any payments by way of royalties, fees or otherwise to any owner or licensor of or claimant to any Intellectual Property with respect to the use thereof in connection with the present conduct of its business other than in the ordinary course of its business.  There are no agreements, understandings, instruments, contracts, judgments, orders or decrees to which the Company is a party or by which it is bound which involve indemnification by the Company with respect to infringements of Intellectual Property, other than in the ordinary course of its business.

 

(ii) No Breach by Employees.  The Company is not aware that any of its employees is obligated under any contract or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would materially interfere with the use of his or her efforts to promote the interests of the Company or that would conflict with the Company’s business as presently conducted.  Neither the execution nor delivery of this Agreement, nor the carrying on of the Company’s business by the employees of the Company, nor the conduct of the Company’s business as presently conducted, will, to the Company’s knowledge, conflict with or result in a breach of the terms, conditions or provisions of, or constitute a default under, any contract, covenant or instrument under which any of such employee is now obligated.  The Company does not believe it is or will be necessary to use any inventions of any of its employees made prior to their employment by the Company of which it is aware.

5.           CERTAIN COVENANTS AND ACKNOWLEDGMENTS.

a.           Covenants and Acknowledgements of Buyer.

 

(i)           Transfer Restrictions.  The Buyer acknowledges that (1) the Securities have not been and are not being registered under the provisions of the 1933 Act and, except as included in an effective registration statement, the Shares have not been and are not being registered under the 1933 Act, and may not be transferred unless (A) subsequently registered thereunder, or (B) the Buyer shall have delivered to the Company an opinion of counsel, reasonably satisfactory in form, scope and substance to the Company, to the effect that the Securities to be sold or transferred may be sold or transferred pursuant to an exemption from such registration; (2) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of said Rule and further, if said Rule is not applicable, any resale of such Securities under circumstances in which the seller, or the Person through whom the sale is made, may be deemed to be an underwriter, as that term is used in the 1933 Act, may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder; and (3) neither the Company nor any other Person is under any obligation to register the Securities under the 1933 Act or to comply with the terms and conditions of any exemption thereunder.

 

 

 

  

10

  

 

(ii)           Restrictive Legend.  The Buyer acknowledges and agrees that, until such time as the relevant Shares have been registered under the 1933 Act, and may be sold in accordance with another effective registration statement, or until such Shares can otherwise be sold without restriction, whichever is earlier, the certificates and other instruments representing any of the Securities shall bear a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of any such Securities):

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES OR AN OPINION OF COUNSEL OR OTHER EVIDENCE ACCEPTABLE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

(iii)           Confession of Judgment.  The Buyer shall not file the Confession of Judgment unless and until an Event of Default (as defined in the Note) shall have occurred.

b.           Covenants, Acknowledgements and Agreements of the Company.  As a condition to the Buyer’s obligation to purchase the Securities contemplated by this Agreement, and as a material inducement for the Buyer to enter into this Agreement and the other Transaction Documents, the Company covenants and agrees as follows:

 

(i)           Filings.  From the date hereof until all the Conversion Shares either have been sold by the Buyer, or may permanently be sold by the Buyer without any restrictions pursuant to Rule 144, (the “Registration Period”), the Company shall  timely make all filings required to be made by it under the 1933 Act, the 1934 Act, Rule 144 or any United States state securities laws and regulations thereof applicable to the Company or by the rules and regulations of the Principal Trading Market and such reports shall conform to the requirement of the applicable laws, regulations and government agencies, and, unless such filing is publicly available on the SEC’s EDGAR system (via the SEC’s web site at no additional charge), to provide a copy thereof to the Buyer promptly after such filing.  Additionally, within four business days following the date of this Agreement, the Company shall file a current report on Form 8-K describing the terms of the transactions contemplated by the Transaction Documents in the form required by the Exchange Act and approved by Buyer and attaching the material transaction documents as exhibits to such filing.  Reference is made to the Section titled “Publicity, Filings, Releases, Etc.” below.  Additionally, the Company shall furnish to the Buyer, so long as the Buyer owns any Purchased Securities or Common Stock, promptly upon request, (1) a written statement by the Company that it has complied with the reporting requirements of Rule 144, (2) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested to permit the Buyer to sell such securities pursuant to Rule 144 without registration.

 

(ii)           Reporting Status.  So long as the Buyer beneficially owns any of the Purchased Securities and for at least twenty (20) Trading Days thereafter, the Company shall file all reports required to be filed with the SEC pursuant to Section 13 or 15(d) of the 1934 Act, shall take all reasonable action under its control to ensure that adequate current public information with respect to the Company, as required in accordance with Rule 144(c)(2) of the 1933 Act, is publicly available, and shall not terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would permit such termination.

 

 

 

  

11

  

 

(iii)           Listing.  The Company’s Common Stock shall be listed or quoted for trading on any of (a) theNYSE Amex, (b) New York Stock Exchange, (c) the Nasdaq Global Market, (d) the Nasdaq Capital Market, or (e) the Nasdaq OTC Bulletin Board. The Company shall promptly secure the listing of all of the Conversion Shares upon each national securities exchange and automated quotation system, if any, upon which the Common Stock is then listed (subject to official notice of issuance) and shall maintain such listing of all securities from time to time issuable under the terms of the Transaction Documents.  The Company will comply in all material respects with the Company’s reporting, filing and other obligations under the by-laws or rules of the Principal Trading Market and/or the Financial Industry Regulatory Authority, Inc. (“FINRA”) or any successor thereto, as the case may be, applicable to it at least through the date which is sixty (60) days after the later of the date on which all of the Note have been converted or have been paid in full.

 

(iv)           Use of Proceeds.  The Company will use the net proceeds received hereunder for working capital and general corporate purposes; provided, however, that the Company will not use such proceeds to pay fees payable (x) to any broker or finder relating to the offer and sale of the Purchased Securities except Galileo, or (y) to any other party who purchased securities or loaned funds to the Company in any financing transaction effected prior to the Closing Date.

 

(v)           Publicity, Filings, Releases, Etc.  Each of the parties agrees that it will not disseminate any information relating to the Transaction Documents or the transactions contemplated thereby, including issuing any press releases, holding any press conferences or other forums, or filing any reports (collectively, “Publicity”), without giving the other party reasonable advance notice and an opportunity to comment on the contents thereof.  Neither party will include in any such Publicity any statement or statements or other material to which the other party reasonably objects, unless in the reasonable opinion of counsel to the party proposing such statement, such statement is legally required to be included.  In furtherance of the foregoing, the Company will provide to the Buyer’s Counsel drafts of the applicable text the first filing of a current report on Form 8-K or a Quarterly or Annual Report on Form 10-Q or 10-K (or equivalent SB forms), as the case may be, intended to be made with the SEC which refers to the Transaction Documents or the transactions contemplated thereby as soon as practicable (but at least two (2) Trading Days before such filing will be made) and will not include in such filing (or any other filing filed before then) any statement or statements or other material to which the other party reasonably objects, unless in the reasonable opinion of counsel to the party proposing such statement, such statement is legally required to be included.  Notwithstanding the foregoing, each of the parties hereby consents to the inclusion of the text of the Transaction Documents in filings made with the SEC (but any descriptive text accompanying or part of such filing shall be subject to the other provisions of this paragraph).  Notwithstanding, but subject to, the foregoing provisions of this  provision, the Company will, after the Closing Date, promptly issue a press release and file a current report on Form 8-K or, if appropriate, a quarterly or annual report on the appropriate form, referring to the transactions contemplated by the Transaction Documents.

 

                (vi)           FINRA Rule 5110. The Company is aware that the Corporate Financing Rule 5110 (“FINRA Rule 5110”) of FINRA is or may become applicable to the transactions contemplated by the Transaction Documents or to the sale by a Holder of any of the Securities. If FINRA Rule 5110 is so applicable, the Company shall, to the extent required by such rule, timely make any filings and cooperate with any broker or selling stockholder in respect of any consents, authorizations or approvals that may be necessary for FINRA to timely and expeditiously permit the stockholder to sell the securities.

 

(vii)           Keeping of Records and Books of Account. The Company shall keep and cause each Subsidiary, if any, to keep adequate records and books of account, in which complete entries will be made in accordance with GAAP consistently applied, reflecting all financial transactions of the Company and such subsidiaries, and in which, for each fiscal year, all proper reserves for depreciation, depletion, obsolescence, amortization, taxes, bad debts and other purposes in connection with its business shall be made.

 

 

 

  

12

  

 

(viii)           Corporate Existence.  The Company shall (a) do all things necessary to preserve and keep in full force and effect its corporate existence, including, without limitation, all licenses or similar qualifications required by it to engage in its business in all jurisdictions in which it is at the time so engaged, (b) continue to engage in business of the same general type as conducted as of the date hereof, and (c) continue to conduct its business substantially as now conducted or as otherwise permitted hereunder.

 

(ix)           Taxes.  The Company shall pay and discharge promptly when due all taxes, assessments and governmental charges or levies imposed upon it or upon its income or profits or in respect of its property before the same shall become delinquent or in default, which, if unpaid, might reasonably be expected to give rise to liens or charges upon such properties or any part thereof, unless, in each case, the validity or amount thereof is being contested in good faith by appropriate proceedings and the Company has maintained adequate reserves with respect thereto in accordance with GAAP.

 

(x)           Stockholder Approval.  The Company shall use its best efforts to obtain approval by the Company’s stockholders of the Transaction Documents at the first meeting of its stockholders following the Closing Date including, without limitation, a waiver of  NYSE Amex Rule 713 (“Rule 713”) in order that the 19.99% Cap shall not apply to any conversions of the Note or any exercise of the Warrant and approval for the issuance of not less than 4,800,001 shares of Common Stock, including the shares of Common Stock contemplated hereby pursuant to the Note and the Warrant, at a discount from book or market value at the time of issuance. Such approval shall be obtained no later than July 15, 2010.  For the avoidance of doubt, in the event the Company fails to obtain such approval, an Event of Default (as defined in the Note) shall occur but the Transaction Documents will remain in full force and effect.

 

(xi)           Compliance. The Company shall comply in all material respects with all federal, state and local laws and regulations, orders, judgments, decrees, injunctions, rules, regulations, permits, licenses, authorizations and requirements applicable to it (collectively, “Requirements”) of all governmental bodies, departments, commissions, boards, companies or associations insuring the premises, courts, authorities, officials or officers which are applicable to the Company, its business, operations, or any of its properties, except where the failure to so comply would not have a Material Adverse Effect on the Company or any of its properties; provided, however, that nothing provided herein shall prevent the Company from contesting the validity or the application of any Requirements.

(xii)           3(a)(10) Shares.  In the event the Company, in violation of the covenants contained herein, ever ceases to be a reporting company for purposes of the 1934 Act for any period of time, then the Company, for so long as Rule 144 is not available to the Buyer as an exemption from registration, shall cause any of its shareholders who at such time are in possession of Common Stock tradable under Section 3(a)(10) of the Securities Act (“3(a)(10) Shares”) to cease to sell such 3(a)(10) Shares.

 

(xiii)           Litigation.  From and after the date hereof and until all of the Company’s obligations hereunder and the Note are paid and performed in full, the Company shall notify the Buyer in writing, promptly upon learning thereof, of any litigation or administrative proceeding commenced or threatened against the Company involving a claim in excess of $100,000.

(xiv)           Performance of Obligations.  The Company shall promptly and in a timely fashion perform and honor all demands, notices, requests and obligations that exist or may arise under the Transaction Documents.

 

 

 

  

13

  

 

(xv)           Listing Approval.  The Company shall have received listing approval from NYSE Amex for the shares of Common Stock issuable upon conversion of the Note and exercise of the Warrant as soon as practicable after Closing, but in no event later than May 1, 2010.

 

(xvi)           Authorized Shares. The Company shall at all times prior to repayment of the Note maintain sufficient authorized and unissued shares of Common Stock as may be necessary to effect the issuance of the Shares upon complete conversion of the Note and exercise of the Warrant. In any event, the Company shall reserve (i) for issuance upon conversion and/or payment of the Note not less than 4,000,000 Shares and (ii) for issuance upon exercise of the Warrant not less than 1,100,000 Shares.

6.           TRANSFER AGENT INSTRUCTIONS.

a.           The Company warrants that, with respect to the Securities, other than the stop transfer instructions to give effect to Section 4(a)(i) hereof, it will give the Transfer Agent no instructions inconsistent with instructions to issue Common Stock from time to time upon conversion of the Note, as may be applicable from time to time, in such amounts as specified from time to time by the Company to the Transfer Agent, bearing the restrictive legend specified in Section 4(a)(ii) of this Agreement prior to registration of the Shares under the 1933 Act, registered in the name of the Buyer or its nominee and in such denominations to be specified by the Holder in connection therewith.  Except as so provided, the Shares shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement and the other Transaction Documents.  Nothing in this Section shall affect in any way the Buyer’s obligations and agreement to comply with all applicable securities laws upon resale of the Securities.  If the Buyer provides the Company with an opinion of counsel reasonably satisfactory to the Company that registration of a resale by the Buyer of any of the Securities in accordance with clause (1)(B) of Section 4(a)(i) of this Agreement is not required under the 1933 Act or upon request from a Holder while the Registration Statement is effective, the Company shall (except as provided in clause (2) of Section 4(a)(i) of this Agreement) permit the transfer of the Securities and, in the case of the Conversion Shares, as may be applicable, use its best efforts to cause the Transfer Agent to promptly electronically transmit to the Holder via the Depository Trust Company (“DTC”) Fast Automated Securities Transfer program such Conversion Shares.  The Company specifically represents that, as of the date hereof and as of the Closing Date, (i) the Company’s Transfer Agent is (a) participating in the DTC program, (b) is DWAC eligible, and (ii)  the Company is not aware of any plans of the Transfer Agent to terminate such DTC participation or DWAC eligibility.  While any Holder holds Securities, the Company shall at all times maintain a transfer agent which participates in the DTC program and is DWAC eligible, and the Company will not appoint any transfer agent which does not both participate in the DTC program and maintain DWAC eligibility.  Nevertheless, in the event the Transfer Agent is not participating in the DTC/DWAC program or the Conversion Shares are not otherwise transferable via the DTC/DWAC program, then the Company shall instruct the Transfer Agent to issue one or more certificates for Common Stock without legend in such name and in such denominations as specified by the Buyer.  In the event the Company’s transfer agent is not DWAC eligible on any Conversion Date, and consequently the Company issues Conversion Shares pursuant to the Conversion Notice in certificated rather than electronic form, then in such event if the closing bid price of the Common Stock on the Principal Trading Market is lower on the date of delivery of the certificates to the Buyer than on the Conversion Date, such difference in the closing bid prices, multiplied by the number of Conversion Shares shall be added to the principal balance of the Note.

 

b.            The Company shall assume any fees or charges of the Transfer Agent or Company Counsel regarding (i) the removal of a legend or stop transfer instructions with respect to Securities, and (ii) the issuance of certificates or DTC registration to or in the name of the Holder or the Holder’s designee or to a transferee as contemplated by an effective Registration Statement.  Notwithstanding the foregoing, it shall be the Holder’s responsibility to obtain all needed formal requirements (specifically: medallion guarantee and prospectus delivery compliance) in connection with any electronic issuance of shares of Common Stock.

 

 

 

  

14

  

 

c.           The Holder of the Note  shall be entitled to exercise its conversion privilege with respect to the Note, as the case may be, notwithstanding the commencement of any case under 11 U.S.C. §101 et seq. (the “Bankruptcy Code”).  In the event the Company is a debtor under the Bankruptcy Code, the Company hereby waives, to the fullest extent permitted, any rights to relief it may have under 11 U.S.C. §362 in respect of such holder’s exercise privilege.  The Company hereby waives, to the fullest extent permitted, any rights to relief it may have under 11 U.S.C. §362 in respect of the conversion of the Note. The Company agrees, without cost or expense to such Holder, to take or to consent to any and all action necessary to effectuate relief under 11 U.S.C. §362.

7.           CLOSING DATE.

 

a.           The Closing Date shall occur on the date which is the first Trading Day after each of the conditions contemplated by Sections 7 and 8 hereof shall have either been satisfied or been waived by the party in whose favor such conditions run, but in any event shall not be later than March 26, 2010.

 

b.           Closing of the purchase and sale of Purchased Securities shall occur on the Closing Date at the offices of the Buyer and shall take place no later than 3:00 P.M., Eastern Time, on such day or such other time as is mutually agreed upon by the Company and the Buyer.

8.           CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL.

The Buyer understands that the Company’s obligation to sell the relevant Purchased Securities to the Buyer pursuant to this Agreement on the Closing Date is conditioned upon:

a.           The execution and delivery of this Agreement and, as applicable, the other Transaction Documents by the Buyer on or before such Closing Date;

b.           Delivery by the Buyer by the Closing Date of good funds as payment in full of an amount equal to the Net Purchase Price in accordance with this Agreement;

 

c.           The accuracy on the Closing Date of the representations and warranties of the Buyer contained in this Agreement, each as if made on such date, and the performance by the Buyer on or before such date of all covenants and agreements of the Buyer required to be performed on or before such date; and

d.           There shall not be in effect any law, rule or regulation prohibiting or restricting the transactions contemplated hereby, or requiring any consent or approval which shall not have been obtained.

9.           CONDITIONS TO THE BUYER’S OBLIGATION TO PURCHASE.

 

Generally.  The Buyer’s obligation to purchase the Purchased Securities is conditioned upon and subject to the fulfillment, on or prior to the Closing Date, of all of the following conditions, any of which may be waived in whole or in part by the Buyer:

a.           The execution and delivery of this Agreement and the other Transaction Documents by the Company on or before the Closing Date;

 

 

 

  

15

  

 

b.           Without limiting the generality of the requirement in the immediately preceding section, the delivery by the Company of the Note and the Warrant in accordance with this Agreement;

c.           On the Closing Date, each of the Transaction Documents executed by the Company on or before such date shall be in full force and effect and the Company shall not be in default thereunder;

 

d.           The accuracy in all material respects on the Closing Date of the representations and warranties of the Company contained in this Agreement and the other Transaction Documents, each as if made on such date, and the performance by the Company on or before such date of all covenants and agreements of the Company required to be performed on or before such date;

e.           There shall not be in effect any law, rule or regulation prohibiting or restricting the transactions contemplated hereby, or requiring any consent or approval which shall not have been obtained; and

 

f.           From and after the date hereof to and including the Closing Date, each of the following conditions will remain in effect: (i) the trading of the Common Stock shall not have been suspended by the SEC or on the Principal Trading Market; (ii) trading in securities generally on the Principal Trading Market shall not have been suspended or limited; (iii), no minimum prices shall been established for securities traded on the Principal Trading Market; (iv) there shall not have been any material adverse change in any financial market; and (v) there shall not have occurred any Material Adverse Effect.

 

g.           Except for any notices required or permitted to be filed after the Closing Date with certain federal and state securities commissions, the Company shall have obtained (a) all governmental approvals required in connection with the lawful sale and issuance of the Securities, and (b) all third party approvals required to be obtained by the Company in connection with the execution and delivery of the Transaction Documents by the Company or the performance of the Company’s obligations thereunder.

 

h.           All corporate and other proceedings in connection with the transactions contemplated at the Closing and all documents and instruments incident to such transactions shall be reasonably satisfactory in substance and form to the Buyer.

10.           INDEMNIFICATION AND REIMBURSEMENT.

 

a.           The Company agrees to defend, indemnify and forever hold harmless the Buyer and its officers, directors, employees, and agents, and each Buyer Control Person (the “Buyer Parties”) from and against any losses, claims, damages, liabilities or expenses incurred (collectively, “Damages”), joint or several, and any action in respect thereof to which the Buyer, its partners, Affiliates, officers, directors, employees, and duly authorized agents, and any such Buyer Control Person becomes subject, resulting from, arising out of or relating to any misrepresentation, breach of warranty or nonfulfillment of or failure to perform any covenant or agreement on the part of Company contained in this Agreement, as such Damages are incurred.  The Buyer Parties with the right to be indemnified under this Section (the “Indemnified Parties”) shall have the right to defend any such action or proceeding with attorneys of their own selection, and the Company shall be solely responsible for all costs and expenses related thereto.  If the Indemnified Parties opt not to retain their own counsel, the Company shall defend any such action or proceeding with attorneys of its choosing at its sole cost and expense, provided that such attorneys have been pre-approved by the Indemnified Parties, which approval shall not be unreasonably withheld, and provided further that the Company may not settle any such action or proceeding without first obtaining the written consent of the Indemnified Parties.

 

 

 

  

16

  

 

b.           The indemnity agreements contained herein shall be in addition to (i) any cause of action or similar rights of the Buyer Parties against the Company or others, and (ii) any liabilities the Company may be subject to.

11.           JURY TRIAL WAIVER.   The Company and the Buyer hereby waive a trial by jury in any action, proceeding or counterclaim brought by either of the Parties hereto against the other in respect of any matter arising out or in connection with the Transaction Documents.

 

12.           SPECIFIC PERFORMANCE.  The Company and  the Buyer acknowledge and agree that irreparable damage would occur in the event that any provision of this Agreement or any of the other Transaction Documents were not performed in accordance with its specific terms or were otherwise breached.  It is accordingly agreed that the parties (including any Holder) shall be entitled to an injunction or injunctions, without (except as specified below) the necessity to post a bond, to prevent or cure breaches of the provisions of this Agreement or such other Transaction Document and to enforce specifically the terms and provisions hereof or thereof, this being in addition to any other remedy to which any of them may be entitled by law or equity; provided, however that the Company, upon receipt of a Notice of Conversion or a Notice of Exercise, may not fail or refuse to deliver the stock certificates and the related legal opinions, if any, or if there is a claim for a breach by the Company of any other provision of this Agreement or any of the other Transaction Documents, the Company shall not raise as a legal defense, based on any claim that the Holder or anyone associated or affiliated with the Holder has violated any provision hereof or any other Transaction Document, has engaged in any violation of law or for any other reason, unless the Company has first posted a bond for one hundred fifty percent (150%) of the principal amount and, if relevant, then obtained a court order specifically directing it not to deliver said stock certificates to the Holder. The proceeds of such bond shall be payable to the Holder to the extent that the Holder obtains judgment or its defense is recognized.  Such bond shall remain in effect until the completion of the relevant proceeding and, if the Holder appeals therefrom, until all such appeals are exhausted.  This provision is deemed incorporated by reference into each of the Transaction Documents as if set forth therein in full.

 

13.           OWNERSHIP LIMITATION. If at any time after the Closing, the Buyer shall receive (or shall attempt to convert the Note into or exercise the Warrant for)  shares of the Common Stock in payment of interest or principal or on conversion of the Note or exercise of the Warrant, so that the Buyer would hold by virtue of such action or receipt of shares of Common Stock under or pursuant to conversion of the Note or exercise of the Warrant a number of shares exceeding 9.99% of the number of shares of the Company’s Common Stock outstanding on such date (the “9.99% Cap”), the Company shall not be obligated and shall not issue to the Buyer shares of its Common Stock which would exceed the 9.99% Cap.

 

14.           NYSE AMEX  19.99% CAP.  The parties understand that the issuance of the Common Stock upon conversion of the Note or exercise of the Warrant may be or may become subject to Rule 713, which requires stockholder approval prior to the issuance of additional shares under certain circumstances.  Accordingly, in the event (i) the Buyer attempts to convert the Note or exercise the Warrant prior the Company’s receipt of such shareholder approval, and (ii) such conversion or exercise would require the Company to issue in excess of 19.99% of the Company’s outstanding Common Stock on the Closing Date, then the Company shall not be obligated to issue to the Buyer any shares that would be in excess of the 19.99% Cap until required approvals are obtained from the stockholders and NYSE Amex; provided, however, that in the event that Rule 713 or other applicable NYSE Amex Rules do not apply, then the Company shall issue all requested shares in accordance with the terms and conditions Transaction Documents.

15.           MISCELLANEOUS.  The Company and the Buyer hereby agree that the provisions of this Section shall apply to all of the Transaction Documents.

 

 

 

  

17

  

 

a.           Governing Law and Venue.  This Agreement shall be governed by and interpreted in accordance with the laws of the State of Illinois for contracts to be wholly performed in such state and without giving effect to the principles thereof regarding the conflict of laws.  Each of the parties consents to the exclusive jurisdiction of the federal courts whose districts encompass any part of the County of Cook or the state courts of the State of Illinois sitting in the County of Cook in connection with any dispute arising under this Agreement or any of the other Transaction Documents and hereby waives, to the maximum extent permitted by law, any objection, including any objection based on forum non conveniens, to the bringing of any such proceeding in such jurisdictions or to any claim that such venue of the suit, action or proceeding is improper. To the extent determined by such court, the Company shall reimburse the Buyer for any reasonable legal fees and disbursements incurred by the Buyer in enforcement of or protection of any of its rights under any of the Transaction Documents.  Nothing in this Section shall affect or limit any right to serve process in any other manner permitted by law.

b.           No Waiver.  Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.

c.           Successors and Assigns.  This Agreement shall inure to the benefit of and be binding upon the successors and assigns of each of the parties hereto.

d.           Pronouns.  All pronouns and any variations thereof refer to the masculine, feminine or neuter, singular or plural, as the context may require.

e.           Counterparts.  This Agreement may be signed in one or more counterparts, each of which shall be deemed an original, but all of which together shall be deemed to constitute one instrument.  Facsimile and email copies of signed signature pages will be deemed binding originals.

f.           Headings.  The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.

 

g.           Severability.  Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such provision shall be modified to achieve the objective of the parties to the fullest extent permitted and such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement or the validity or enforceability of this Agreement in any other jurisdiction.

h.           Amendment.  This Agreement may be amended only by an instrument in writing signed by the party to be charged with enforcement thereof.

 

i.           Entire Agreement.  This Agreement together with the other Transaction Documents constitute and contain the entire agreement between the Company and the Buyer and supersede all prior agreements and understandings among the parties hereto with respect to the subject matter hereof.

j.           Currency.  All dollar amounts referred to or contemplated by this Agreement or any other Transaction Document shall be deemed to refer to US Dollars, unless otherwise explicitly stated to the contrary.

 

k.           Buyer’s Expenses.  Except as otherwise provided herein, the Company and the Buyer shall be responsible for paying such party’s own fees and expenses (including legal expenses) incurred in connection with the preparation and negotiation of the Transaction Documents and the closing of the transactions contemplated thereby.

 

 

 

  

18

  

 

l.           Assignment by the Company.  Notwithstanding anything to the contrary herein, the rights, interests or obligations hereunder may not be assigned, by operation of law or otherwise, in whole or in part, by the Company without the prior written consent of the Buyer, which consent may be withheld at the sole discretion of the Buyer; provided, however, that in the case of a merger, sale of substantially all of the Company’s assets or other corporate reorganization, the Buyer shall not unreasonably withhold, condition or delay such consent.

 

m.           Advice of Counsel. In connection with the preparation of this Agreement and all other Transaction Documents, each of the Company, its shareholders, officers, agents, and representatives acknowledges and agrees that the attorney that prepared this Agreement and all of the other Transaction Documents acted as legal counsel to the Buyer only.  Each of the Company, its shareholders, officers, agents, and representatives (i) hereby acknowledges that he/she/it has been, and hereby is, advised to seek legal counsel and to review this Agreement and all of the other Transaction Documents with legal counsel of his/her/its choice, and (ii) either has sought such legal counsel or hereby waives the right to do so.

n.           No Strict Construction. The language used in this Agreement is the language chosen mutually by the parties hereto and no doctrine of construction shall be applied for or against any party.

o.           Attorneys’ Fees.  In the event of any action at law or in equity to enforce or interpret the terms of this Agreement or any of the other Transaction Documents, the Prevailing Party (as defined hereafter) shall be entitled to reasonable attorneys’ fees, court costs and collection costs in addition to any other relief to which such party may be entitled.  “Prevailing Party” shall mean the party in any litigation or enforcement action that prevails in the highest number of final rulings, counts or judgments adjudicated by a court of competent jurisdiction.

p.           Replacement of the Note. Subject to any restrictions on or conditions to transfer set forth in the Note, the Holder of a Note, at its option, may in person or by duly authorized attorney surrender the same for exchange at the Company’s chief executive office, and promptly thereafter and at the Company’s expense, except as provided below, receive in exchange therefor one or more new convertible secured promissory note(s), each in the principal requested by such Holder, dated the date to which interest shall have been paid on the Note so surrendered or, if no interest shall have yet been so paid, dated the date of the Note so surrendered and registered in the name of such person or persons as shall have been designated in writing by such holder or its attorney for the same principal amount as the then unpaid principal amount of the Note so surrendered. As applicable, upon receipt by the Company of evidence reasonably satisfactory to it of the ownership of and the loss, theft, destruction or mutilation of a Note and (a) in the case of loss, theft or destruction, of indemnity reasonably satisfactory to it; or (b) in the case of mutilation, upon surrender thereof, the Company, at its expense, will execute and deliver in lieu thereof a new convertible secured promissory note executed in the same manner as the Note being replaced, in the same principal amount as the unpaid principal amount of such Note and dated the date to which interest shall have been paid on such Note or, if no interest shall have yet been so paid, dated the date of such Note.

16.           NOTICES.  Any notice required or permitted hereunder shall be given in writing (unless otherwise specified herein) and shall be deemed effectively given on the earliest of

(a) the date delivered, if delivered by personal delivery as against written receipt therefor or by confirmed facsimile transmission,

 

 

 

  

19

  

 

(b) the fifth Trading Day after deposit, postage prepaid, in the United States Postal Service by registered or certified mail,

(c) the third Trading Day after mailing by domestic or international express courier, with delivery costs and fees prepaid, or

(d) when faxed or sent by electronic mail, upon confirmation of receipt,

in each case, addressed to each of the other parties thereunto entitled at the following addresses (or at such other addresses as such party may designate by ten (10) days’ advance written notice similarly given to each of the other parties hereto):

COMPANY:                          At the address set forth at the head of this Agreement.

Attn: Chief Executive Officer

Telephone No.: 714 505-4461

Telecopier No.: 714 505-4464

BUYER:                                At the address set forth on the signature page of this Agreement.

with a copy (which shall not constitute notice) to:

Bennett Tueller Johnson & Deere, P.C.

3165 East Millrock Drive, Suite 500

Salt Lake City, Utah 84121

Attn: Jonathan K. Hansen, Esq.

Telephone No.: (801) 438-2000

Telecopier No.  (801) 438-2050

17.           SURVIVAL OF REPRESENTATIONS AND WARRANTIES. The Company’s and the Buyer’s representations and warranties herein shall survive the execution and delivery of this Agreement and the delivery of the Transaction Documents and the payment of the Net Purchase Price and shall inure to the benefit of the Buyer and the Company and their respective successors and assigns.

[BALANCE OF PAGE INTENTIONALLY LEFT BLANK]

 

 

 

 

 

 

 

  

20

  

IN WITNESS WHEREOF, each of the undersigned represents that the foregoing statements made by it above are true and correct and that it has caused this Agreement to be duly executed on its behalf (if an entity, by one of its officers thereunto duly authorized) as of the date first above written.

NET PURCHASE PRICE:                    $540,000.00

BUYER:

ISP HOLDINGS, LLC

By:  ___________________________

Name:  _________________________

Its:  ____________________________

303 East Wacker Drive, Suite 311

Chicago, Illinois  60601

Facsimile No.: (312) 819-9701

COMPANY:

RADIENT PHARMACEUTICALS CORPORATION

By: ____________________________

Name: __________________________

                                                                                               Title: ___________________________

 

 

 

 

 

 

 

 

 

 

[SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENT]

 

  

21

  

 

 

	 	ANNEX I	COMPANY'S SEC DOCUMENTS 
	  	  	  
	  	
ANNEX II

	
DISCLOSURE ANNEX

	  	  	  
	  	
ANNEX III

	
DISBURSEMENT INSTRUCTIONS

	  	  	  
	  	
ANNEX IV

	
REGISTRATION RIGHTS AGREEMENT

	  	  	  
	  	
ANNEX V

	
CONFESSION OF JUDGMENT

	  	  	  
	  	
ANNEX VI

	
UNANIMOUS WRITTEN CONSENT OF THE BOARD

	  	  	  
	  	
ANNEX VII

	
OFFICER CERTIFICATE

	  	  	  
	  	
ANNEX VIII

	
NOTE

	  	  	  
	  	
ANNEX IX

	
WARRANT

 

 

 

 

 

 

  

22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]